AGC株式会社
AGCグループはグローバルにバイオ医薬品原薬の受託開発・製造事業を展開しています。豊富な実績と高度な技術に基づき、バイオ医薬品原薬の開発段階から商用段階までをサポートしています。
会社カテゴリー：原薬・添加剤・中間体、製造受託機関(CMO)、医薬品製造、再生医療関連
主サービス提供地域：日本、アメリカ合衆国、ヨーロッパ(イギリス以外)、イギリス、アジア
製品・サービス詳細
AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV) and retroviral vectors (RVV). The AGC Biologics viral vector program at our flagship Milan site has supported three commercial products to-date.
Our ready-to-use platform capabilities are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house.
Our quality systems, manufacturing scales, and regulatory expertise allow us to meet both clinical and commercial viral vector demands. Moreover, our scale-down capabilities provide flexible and cost-effective solutions for process development and pre-clinical studies.
Viral Vector Production and Manufacturing Services
-
Viral Vector services including development, characterization, and manufacturing (PD/cGMP environment)
-
Small, medium, and large-scale equipment for both adhesion and suspension-based processes
-
A plug-and-play platform for large-scale vector manufacturing that can be adapted to virtually any program
-
A reliable and flexible platform for various scales of AAV production with different serotypes
-
cGMP viral vector manufacturing at various scales across up to 2,000L across two global sites
-
160+ in-house analytical tests with custom designs for clinical and commercial supply
-
Global quality systems and teams of scientists with two decades of global regulatory experience in the cell and gene field